Somatostatin (SRIF) modulates distinct signaling pathways in rat pituitary tumor cells; negative coupling of SRIF receptor subtypes 1 and 2 to arachidonic acid release

Naunyn Schmiedebergs Arch Pharmacol. 2002 Mar;365(3):200-9. doi: 10.1007/s00210-001-0509-7. Epub 2002 Feb 1.

Abstract

The somatotropin release-inhibiting factor somatostatin-14 (SRIF) is known to activate distinct receptor subtypes (sst1-5). In rat pituitary tumor cells (GC cells), sst2 but not sst1 receptors mediate the SRIF-induced inhibition of intracellular concentration of Ca2+ ([Ca2+]i) and are negatively coupled to cAMP-dependent pathways. In the present study, transduction mechanisms coupling distinct SRIF receptors to their specific functional role were investigated with the use of both SRIF agonists with well-known affinity at individual SRIF receptors and the sst2 receptor antagonist L-Tyr(8) isomer of Cyanamid 154806 (CYN-154806). Our results demonstrate that sst1 and sst2 receptors are coupled to distinct signaling pathways in GC cells. In particular, sst2 receptors are negatively coupled to the cAMP-dependent pathway and this pathway is partially responsible for the sst2 receptor-mediated inhibition of [Ca2+]i. In addition, sst1 and sst2 receptors are both coupled to a decrease of arachidonic acid (AA) release with an efficacy similar to that of SRIF, suggesting that SRIF reduces AA release through either a partial activation of both receptors or the activation of one at a time. This finding is important given the well-accepted role for phospholipase A2 (PLA2) as a positive signaling component in transduction pathways of SRIF receptors. sst1 and sst2 receptor negative coupling to PLA2/AA pathways does not seem to be implicated in the SRIF-induced inhibition of [Ca2+]i. The possible role for the SRIF-mediated inhibition of AA release in GC cell function remains to be elucidated.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Arachidonic Acid / metabolism*
  • Calcium / metabolism*
  • Cyclic AMP / metabolism
  • Dose-Response Relationship, Drug
  • Octreotide / pharmacology
  • Oligopeptides / pharmacology
  • Phospholipases A / metabolism
  • Phospholipases A2
  • Pituitary Neoplasms / metabolism*
  • Pituitary Neoplasms / pathology
  • Rats
  • Receptors, Somatostatin / agonists
  • Receptors, Somatostatin / antagonists & inhibitors
  • Receptors, Somatostatin / metabolism*
  • Signal Transduction*
  • Somatostatin / analogs & derivatives*
  • Somatostatin / metabolism*
  • Somatostatin / pharmacology
  • Tumor Cells, Cultured

Substances

  • CH 275
  • CYN 154806
  • Oligopeptides
  • Receptors, Somatostatin
  • somatostatin receptor type 1
  • Arachidonic Acid
  • Somatostatin
  • somatostatin receptor 2
  • Cyclic AMP
  • Phospholipases A
  • Phospholipases A2
  • Octreotide
  • Calcium